Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1982 2
1983 4
1984 3
1985 2
1986 8
1987 1
1988 3
1989 2
1990 7
1991 5
1992 6
1993 5
1994 4
1995 4
1996 11
1997 10
1998 4
1999 2
2000 5
2001 2
2002 2
2003 4
2004 3
2005 6
2006 7
2007 7
2008 7
2009 9
2010 7
2011 9
2012 10
2013 5
2014 11
2015 7
2016 6
2017 4
2018 9
2019 7
2020 7
2021 9
2022 10
2023 7
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. Among authors: zamora p. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-De Dueñas E, Carañana V, Amillano K, Mina L, Malfettone A, Cortés J, Llombart-Cussac A. Di Cosimo S, et al. Among authors: zamora p. Oncologist. 2023 Jan 18;28(1):23-32. doi: 10.1093/oncolo/oyac205. Oncologist. 2023. PMID: 36239405 Free PMC article. Clinical Trial.
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz-Borrego M, Gavilá J, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez de Dueñas E, Amillano K, Shimizu E, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Di Cosimo S, et al. Among authors: zamora p. Breast. 2024 Aug;76:103761. doi: 10.1016/j.breast.2024.103761. Epub 2024 Jun 11. Breast. 2024. PMID: 38880077 Free PMC article. Clinical Trial.
[Neoplastic hypercalcemia].
González Barón M, de la Gándara Porres I, Zamora P, García de Paredes M. González Barón M, et al. Among authors: zamora p. Med Clin (Barc). 1992 Apr 25;98(16):631-4. Med Clin (Barc). 1992. PMID: 1630170 Review. Spanish. No abstract available.
Clinical Probes for ROS and Oxidative Stress.
Zamora PL, Villamena FA. Zamora PL, et al. 2020 Aug 9. In: Berliner LJ, Parinandi NL, editors. Measuring Oxidants and Oxidative Stress in Biological Systems [Internet]. Cham (CH): Springer; 2020. Chapter 3. 2020 Aug 9. In: Berliner LJ, Parinandi NL, editors. Measuring Oxidants and Oxidative Stress in Biological Systems [Internet]. Cham (CH): Springer; 2020. Chapter 3. PMID: 33411445 Free Books & Documents. Review.
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: zamora p. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A, Redondo A, Zamora P, Castelo B, Espinosa E. Pinto A, et al. Among authors: zamora p. Anticancer Drugs. 2010 Nov;21(10):890-6. doi: 10.1097/CAD.0b013e32833e83b2. Anticancer Drugs. 2010. PMID: 20729712 Review.
Gene profiling in breast cancer: time to move forward.
Espinosa E, Vara JÁ, Navarro IS, Gámez-Pozo A, Pinto A, Zamora P, Redondo A, Feliu J. Espinosa E, et al. Among authors: zamora p. Cancer Treat Rev. 2011 Oct;37(6):416-21. doi: 10.1016/j.ctrv.2010.12.009. Epub 2011 Feb 1. Cancer Treat Rev. 2011. PMID: 21277684 Review.
243 results